Have a feature idea you'd love to see implemented?
Let us know!
INO Inovio Pharmaceuticals Inc
Price (delayed)
$5.67
Market cap
$147.22M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$5.11
Enterprise value
$125.81M
INOVIO is a biotechnology company focused on rapidly bringing to market precisely designed DNA medicines to treat and protect people from infectious diseases, cancer, and diseases associated with HPV. INOVIO
Highlights
Inovio Pharmaceuticals's debt has shrunk by 58% YoY and by 3.3% QoQ
INO's EPS is up by 35% year-on-year and by 8% since the previous quarter
The equity has contracted by 43% YoY but it has grown by 2.4% from the previous quarter
INO's quick ratio is up by 10% year-on-year but it is down by 8% since the previous quarter
INO's revenue has dropped by 94% year-on-year and by 17% since the previous quarter
The gross profit has dropped by 94% year-on-year and by 17% since the previous quarter
Key stats
What are the main financial stats of INO
Market
Valuations
Earnings
Shares outstanding
25.96M
Market cap
$147.22M
Enterprise value
$125.81M
Price to earnings (P/E)
N/A
Price to book (P/B)
1.52
Price to sales (P/S)
260.55
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
212.56
Revenue
$591,859
EBIT
-$120.87M
EBITDA
-$118.07M
Free cash flow
-$112.7M
Per share
Balance sheet
Liquidity
EPS
-$5.11
Free cash flow per share
-$4.14
Book value per share
$3.73
Revenue per share
$0.02
TBVPS
$4.92
Total assets
$133.8M
Total liabilities
$37.06M
Debt
$12.98M
Equity
$96.74M
Working capital
$91.16M
Debt to equity
0.13
Current ratio
4.45
Quick ratio
4.25
Net debt/EBITDA
0.18
Margins
Efficiency
Dividend
EBITDA margin
-19,949.1%
Gross margin
100%
Net margin
-20,552.3%
Operating margin
-21,564%
Return on assets
-77.6%
Return on equity
-108.9%
Return on invested capital
-98.6%
Return on capital employed
-112.5%
Return on sales
-20,421.6%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
INO stock price
How has the Inovio Pharmaceuticals stock price performed over time
Intraday
1.98%
1 week
-0.53%
1 month
-1.9%
1 year
27.13%
YTD
-7.35%
QTD
-1.9%
Financial performance
How have Inovio Pharmaceuticals's revenue and profit performed over time
Revenue
$591,859
Gross profit
$591,859
Operating income
-$127.63M
Net income
-$121.64M
Gross margin
100%
Net margin
-20,552.3%
INO's revenue has dropped by 94% year-on-year and by 17% since the previous quarter
The gross profit has dropped by 94% year-on-year and by 17% since the previous quarter
INO's net income is up by 28% year-on-year and by 2.6% since the previous quarter
INO's operating income is up by 26% YoY and by 2.9% QoQ
Growth
What is Inovio Pharmaceuticals's growth rate over time
Valuation
What is Inovio Pharmaceuticals stock price valuation
P/E
N/A
P/B
1.52
P/S
260.55
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
212.56
INO's EPS is up by 35% year-on-year and by 8% since the previous quarter
The stock's price to book (P/B) is 83% less than its 5-year quarterly average of 8.6 and 22% less than its last 4 quarters average of 1.9
The equity has contracted by 43% YoY but it has grown by 2.4% from the previous quarter
INO's revenue has dropped by 94% year-on-year and by 17% since the previous quarter
The P/S is 24% lower than the 5-year quarterly average of 335.3 and 8% lower than the last 4 quarters average of 276.9
Efficiency
How efficient is Inovio Pharmaceuticals business performance
INO's return on assets is down by 43% year-on-year and by 13% since the previous quarter
INO's ROE is down by 39% YoY and by 13% from the previous quarter
The company's return on invested capital fell by 28% YoY and by 10% QoQ
INO's return on sales is down by 18% since the previous quarter
Dividends
What is INO's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for INO.
Financial health
How did Inovio Pharmaceuticals financials performed over time
The total assets has declined by 43% year-on-year but it has grown by 3.6% since the previous quarter
The company's total liabilities fell by 42% YoY but it rose by 7% QoQ
Inovio Pharmaceuticals's debt is 87% lower than its equity
Inovio Pharmaceuticals's debt has shrunk by 58% YoY and by 3.3% QoQ
The equity has contracted by 43% YoY but it has grown by 2.4% from the previous quarter
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.